Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Dow
Johnson and Johnson
Baxter
Harvard Business School

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

MEPRON Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Mepron patents expire, and when can generic versions of Mepron launch?

Mepron is a drug marketed by Glaxosmithkline Llc and is included in two NDAs.

The generic ingredient in MEPRON is atovaquone. There are sixteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the atovaquone profile page.

Drug patent expirations by year for MEPRON
Drug Prices for MEPRON

See drug prices for MEPRON

Recent Clinical Trials for MEPRON

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
William Marsh Rice UniversityEarly Phase 1
Baylor College of MedicineEarly Phase 1
Texas Children's HospitalEarly Phase 1

See all MEPRON clinical trials

Pharmacology for MEPRON
Synonyms for MEPRON
1,4-Naphthalenedione, 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-
1,4-Naphthalenedione, 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-, trans-
1,4-Naphthalenedione, 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-
1,4-Naphthalenedione, 2-[cis-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-
1,4-Naphthalenedione, 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy
1,4-naphthalenedione,2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-
137732-39-9
2-((1r,4r)-4-(4-chlorophenyl)cyclohexyl)-3-hydroxynaphthalene-1,4-dione
2-(4-(4-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-nap
2-(4-(4-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone
2-(TRANS-4-(4-CHLOROPHENYL)CYCLOHEXYL)-3-HYDROXY-1,4-NAPHTHALENEDIONE
2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxynaphthalene-1,4-dione
2-(trans-4-(p-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone
2-[4-(4-chlorophenyl)cyclohexy]-3-hydroxy-1,4-naphthoquinone
2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-dihydronaphthalene-1,4-dione
2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone
2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-napthoquinone
2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1.4-naphthoquinone
2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-naphthalene-1,4-dione
2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione
2-[4-(4-Chlorophenyl)cyclohexyl]-3-hydroxynaphthoquinone, trans-
2-[trans-4-(4-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione
2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone
2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione
2-[trans-4-(p-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone
2-Hydroxy-3-[4-(4-chlorophenyl)cyclohexyl]-1,4-naphthoquinone
233A184
3-[4-(4-Chlorophenyl)cyclohexyl]-4-hydroxy-1,2-naphthalenedione
3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxy-naphthalene-1,2-dione
3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione
3-[4-(p-chlorophenyl)cyclohexyl]-4-hydroxy-1,2-naphthoquinone
566C
566C80
78668-EP2307343A1
94015-53-9
95233-18-4
AB00053222_04
AB00053222_05
AB00053222-03
AB0012456
AB00513855
AB0107187
AB0211463
AC-30251
AC1L2MZG
AC1Q6E9K
Acuvel
AK544285
AKOS005567953
AKOS015895691
AKOS015961933
AN-6439
AS-12809
Atavaquone
ATO & IL-12
ATOVAQUONE
Atovaquone (Atavaquone)
Atovaquone (JAN/USP/INN)
Atovaquone [USAN:BAN:INN]
Atovaquone [USAN:USP:INN:BAN]
Atovaquone & Interleukin 12
Atovaquone EP Impurity B
ATOVAQUONE-D4
Atovaquone, >=98% (HPLC)
BC208879
BCP09477
BDBM192009
BIDD:GT0849
BPBio1_000603
BSPBio_000547
BSPBio_002681
BW 566C
BW 566C-80
BW 566C80
BW-556C-80
BW-566C
BW-566C-80
BW-A 566C
C06835
C22H19ClO3
CAS-95233-18-4
CCG-220534
CCG-39090
CHEBI:575568
CHEBI:95346
CHEMBL222334
CHEMBL519462
Cis-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone
cis-Atovaquone
CRL-8131 & Atovaquone
CS-2702
CTK5H7581
D00236
DB01117
DivK1c_006782
DRG-0084
DSSTox_CID_2629
DSSTox_GSID_22629
DSSTox_RID_76664
DTXSID7022629
FD7252
FT-0081084
FT-0602868
GTPL9695
HMS1569L09
HMS1922F19
HMS2089M14
HMS2093C10
HMS2096L09
HMS2235N08
HMS3369N09
HMS3651N20
HMS3713L09
HSDB 7083
HY-13832
I06-0872
J90007
KB-270797
KBio1_001726
KBio2_002223
KBio2_004791
KBio2_007359
KBio3_001901
KBioGR_001594
KBioSS_002223
KS-00000FO3
KUCQYCKVKVOKAY-CTYIDZIISA-N
KUCQYCKVKVOKAY-OTVXOJSOSA-N
KUCQYCKVKVOKAY-UHFFFAOYSA-N
LS-178256
MCULE-7318126574
Mepron (antipneumocystic)
Mepron (TN)
MLS002153863
MolPort-003-666-542
MolPort-006-167-710
NAP016
NCGC00016961-01
NCGC00016961-02
NCGC00016961-03
NCGC00016961-04
NCGC00016961-06
NCGC00016961-07
NCGC00095113-01
NCGC00095113-02
NSC-759582
NSC759582
Pharmakon1600-01504210
Prestwick0_000534
Prestwick1_000534
Prestwick2_000534
Prestwick3_000534
s3079
SBI-0052893.P002
SC-15688
SC-21393
SCHEMBL1542719
SCHEMBL1649508
SCHEMBL21694
SCHEMBL21695
SCHEMBL637069
SCHEMBL9975142
SCHEMBL9975229
SMR001233220
SPBio_001849
SPBio_002468
SpecPlus_000686
Spectrum_001743
SPECTRUM1504210
Spectrum2_001665
Spectrum3_000991
Spectrum4_001117
Spectrum5_001382
SR-05000001438
SR-05000001438-1
SR-05000001438-2
SR-05000001438-4
SR-05000001438-5
STK636160
SW219222-1
Tox21_110714
Tox21_110714_1
trans-2-[4-(4-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione
trans-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone
TX-010638
UNII-Y883P1Z2LT
Wellvone
Y883P1Z2LT
Z1541632806
ZINC100017856
ZINC100345537
ZINC116473771
ZINC12504271
ZINC299873031
Paragraph IV (Patent) Challenges for MEPRON
Tradename Dosage Ingredient NDA Submissiondate
MEPRON SUSPENSION;ORAL atovaquone 020500 2009-10-20

US Patents and Regulatory Information for MEPRON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Llc MEPRON atovaquone SUSPENSION;ORAL 020500-001 Feb 8, 1995 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Glaxosmithkline Llc MEPRON atovaquone TABLET;ORAL 020259-001 Nov 25, 1992 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for MEPRON

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Llc MEPRON atovaquone SUSPENSION;ORAL 020500-001 Feb 8, 1995   Start Trial   Start Trial
Glaxosmithkline Llc MEPRON atovaquone TABLET;ORAL 020259-001 Nov 25, 1992   Start Trial   Start Trial
Glaxosmithkline Llc MEPRON atovaquone TABLET;ORAL 020259-001 Nov 25, 1992   Start Trial   Start Trial
Glaxosmithkline Llc MEPRON atovaquone SUSPENSION;ORAL 020500-001 Feb 8, 1995   Start Trial   Start Trial
Glaxosmithkline Llc MEPRON atovaquone SUSPENSION;ORAL 020500-001 Feb 8, 1995   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
McKesson
Johnson and Johnson
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.